359 related articles for article (PubMed ID: 38561743)
1. CIP/KIP and INK4 families as hostages of oncogenic signaling.
Csergeová L; Krbušek D; Janoštiak R
Cell Div; 2024 Apr; 19(1):11. PubMed ID: 38561743
[TBL] [Abstract][Full Text] [Related]
2. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development.
Nakayama K; Nakayama K
Bioessays; 1998 Dec; 20(12):1020-9. PubMed ID: 10048302
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody probes for p21WAF1/CIP1 and the INK4 family of cyclin-dependent kinase inhibitors.
Thullberg M; Welcker M; Bartkova J; Kjerulff AA; Lukas J; Högberg J; Bartek J
Hybridoma; 2000 Feb; 19(1):63-72. PubMed ID: 10768842
[TBL] [Abstract][Full Text] [Related]
4. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines.
Sangfelt O; Erickson S; Einhorn S; Grandér D
Oncogene; 1997 Jan; 14(4):415-23. PubMed ID: 9053838
[TBL] [Abstract][Full Text] [Related]
5. Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.
Mainprize TG; Taylor MD; Rutka JT; Dirks PB
J Neurooncol; 2001 Feb; 51(3):205-18. PubMed ID: 11407593
[TBL] [Abstract][Full Text] [Related]
6. Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients.
Chim CS; Fung TK; Wong KF; Lau JS; Law M; Liang R
J Clin Pathol; 2006 Sep; 59(9):921-6. PubMed ID: 16565223
[TBL] [Abstract][Full Text] [Related]
7. p21 promotes gemcitabine tolerance in A549 cells by inhibiting DNA damage and altering the cell cycle.
Fu T; Ma X; Du SL; Ke ZY; Wang XC; Yin HH; Wang WX; Liu YJ; Liang AL
Oncol Lett; 2023 Nov; 26(5):471. PubMed ID: 37809050
[TBL] [Abstract][Full Text] [Related]
8. Cellular senescence: a double-edged sword in cancer therapy.
Xiao S; Qin D; Hou X; Tian L; Yu Y; Zhang R; Lyu H; Guo D; Chen XZ; Zhou C; Tang J
Front Oncol; 2023; 13():1189015. PubMed ID: 37771436
[TBL] [Abstract][Full Text] [Related]
9. CBX8 promotes lung adenocarcinoma growth and metastasis through transcriptional repression of CDKN2C and SCEL.
Chen H; Su Y; Yang L; Xi L; Li X; Lan B; Liu M; Xuan C
J Cell Physiol; 2023 Nov; 238(11):2710-2723. PubMed ID: 37733753
[TBL] [Abstract][Full Text] [Related]
10. PIK3R3 is upregulated in liver cancer and activates Akt signaling to control cancer growth by regulation of CDKN1C and SMC1A.
Lin W; Wang K; Mo J; Wang L; Song Z; Jiang H; Wang C; Jin C
Cancer Med; 2023 Jul; 12(13):14413-14425. PubMed ID: 37212524
[TBL] [Abstract][Full Text] [Related]
11. Ablation of p57+ Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors.
Oka T; Higa T; Sugahara O; Koga D; Nakayama S; Nakayama KI
Cancer Res; 2023 May; 83(9):1393-1409. PubMed ID: 36880956
[TBL] [Abstract][Full Text] [Related]
12. p15
Park SS; Lee YK; Park SH; Lim SB; Choi YW; Shin JS; Kim YH; Kim JH; Park TJ
Heliyon; 2023 Feb; 9(2):e13170. PubMed ID: 36785830
[TBL] [Abstract][Full Text] [Related]
13. CDK inhibitors from past to present: A new wave of cancer therapy.
Mughal MJ; Bhadresha K; Kwok HF
Semin Cancer Biol; 2023 Jan; 88():106-122. PubMed ID: 36565895
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
